

Joint Symposium 17

Oncology & Theranostics Committee / Working Group Internistic Oncology (AIO)

Tuesday, October 15, 08:00-09:30

Session Title

Challenge Pancreatic Cancer

Chairpersons

Ken Herrmann (Essen, Germany)

Jens Siveke (Essen, Germany / AIO)

Programme

08:00 - 08:20 Aldo Scarpa (Verona, Italy): Diagnostic Challenges of PDAC

08:20 - 08:40 Jens Siveke (Essen, Germany / AIO): Treatment Algorithm of PDAC

08:45 - 09:05 Patrick Veit-Haibach (Toronto, Canada): Challenge Diagnostic Imaging of PDAC

09:05 - 09:30 Frederik Giesel (Heidelberg, Germany): Is PDAC an Indication for Radioligand Therapy?

Educational

1. To understand the Clinical Challenge for Imaging and Therapy of Pancreatic Ductal Adenocarcinoma (PDAC)
2. Learn the current treatment algorithm for PDAC patients
3. Learn about the currently established hybrid imaging options
4. Understand the relevance and potential of new targets for receptor-directed imaging and therapy of PDAC

Summary

Pancreatic cancer shows an increasing incidence rise in many countries, with an approximately 45% increase over the past decade. Pancreatic ductal adenocarcinoma (PDAC), which is considered incurable, accounts for more than 90% of pancreatic cancer cases. Despite some improvement, the 5-year and 10-year survival rates for PDAC remain low.

PDAC remains a challenge for diagnostic imaging, and despite recent success of receptor-targeted radioligand therapy in various tumor entities (e.g. neuroendocrine tumors and prostate cancer) there is currently no radioligand therapy for PDAC patients available. Preliminary promising data for Neurotensin 1 receptor- and Fibroblast Activated Protein-directed imaging and therapy is available.

In this session the attendants will learn about the diagnostic challenges of PDAC, the currently existing treatment algorithm, the state of the art diagnostic imaging options as well as new receptor targeted imaging and therapy opportunities.

Key Words

PDAC, diagnostic imaging, new PDCA targets